ResBiotic develops probiotic and pharmabiotic therapies to alleviate neutrophilic inflammation associated with dysbiosis.
ResBiotic has raised $8.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
ResBiotic's investors include Biostack Ventures, Sororibus Capital, Timberline Investments.
ResBiotic is headquartered in Vestavia Hills, United States.
ResBiotic develops probiotic and pharmabiotic therapies to alleviate neutrophilic inflammation associated with dysbiosis.
ResBiotic is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ResBiotic — Funding & Investors." VCBacked, September 12, 2025, https://www.vcbacked.co/company/resbiotic. Accessed August 1, 2026.
VCBacked. (2025). ResBiotic — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/resbiotic
{{cite web |title=ResBiotic — Funding & Investors |url=https://www.vcbacked.co/company/resbiotic |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated